Advertisement

Effect of short-term corticosteroid usage on acute urinary toxicity following Cs-131 prostate brachytherapy

      ABSTRACT

      PURPOSE

      To evaluate short-term patient reported urinary quality of life scores in patients with prostate cancer treated at our institution with and without perioperative prednisone following Cesium-131 (131Cs) prostate LDR brachytherapy.

      METHODS AND MATERIALS

      We started routinely using a perioperative 7-day course of prednisone at a dose of 5 mg per day, beginning 1 day prior to 131Cs prostate LDR brachytherapy from 2013 with goal of improving acute urinary symptomatology. One hundred consecutive patients treated with prednisone were selected, with comparison to 100 consecutive patients who were not treated with prednisone. We analyzed for differences in mean change with standard deviation (SD) in EPIC and AUA scores at 0.5–1 month and 3 months with or without prednisone by Mann-Whitney U Test. Binary logistic regression was performed to assess for impact of prednisone on postoperative urinary catheter use.

      RESULTS

      Pretreatment EPIC and AUA scores were available in 197 patients. Less reduction in EPIC US score was noted at 0.5–1.0 month in the group who received prednisone with mean change of -22.9 (SD 15.4) when compared to the group who did not receive prednisone with mean change of -31.7 (SD 19.3), p < 0.01, with significance lost at 3 months. There was no significant difference in acute urinary retention requiring postoperative urinary catheter placement with perioperative prednisone (OR 1.13, p = 0.71).

      CONCLUSIONS

      A short course of perioperative low-dose prednisone was associated with less severe worsening in urinary symptoms by the EPIC questionnaire at the 0.5–1.0-month timepoint suggesting some improvement in acute urinary quality of life, although differences did not remain statistically significant at 3 months.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Brachytherapy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Morris W.J.
        • Tyldesley S.
        • Rodda S.
        Androgen suppression combined with elective nodal and dose escalated radiation therapy (the ASCENDE-RT Trial): An analysis of survival endpoints for a randomized trial comparing a low-dose-rate brachytherapy boost to a dose-escalated external beam boost for high- and intermediate-risk prostate cancer.
        Int J Radiat Oncol Biol Phys. 2017; 98: 275-285
        • Rodda S.
        • Tyldesley S.
        • Morris W.J.
        ASCENDE-RT: An analysis of treatment-related morbidity for a randomized trial comparing a low-dose-rate brachytherapy boost with a dose-escalated external beam boost for high- and intermediate-risk prostate cancer.
        Int J Radiat Oncol Biol Phys. 2017; 98: 286-295
        • Schaeffer E.
        • Srinivas S.
        • Antonarakis E.S.
        NCCN Guidelines Insights: Prostate cancer, version 1.2021.
        J Natl Compr Canc Netw. 2021; 19: 134-143
        • Neal D.E.
        • Metcalfe C.
        • Donovan J.L.
        Ten-year mortality, disease progression, and treatment-related side effects in men with localised prostate cancer from the ProtecT randomised controlled trial according to treatment received.
        Eur Urol. 2020; 77: 320-330
        • Jacobs B.L.
        • Smith R.P.
        • Beriwal S.
        • Benoit R.M.
        Acute lower urinary tract symptoms after prostate brachytherapy with cesium-131.
        Urology. 2010; 76: 1143-1147
        • Bakhshabadi M.
        • Ghorbani M.
        • Khosroabadi M.
        • et al.
        A comparison study on various low energy sources in interstitial prostate brachytherapy.
        J Contemp Brachytherapy. 2016; 8: 74-81
        • Stone N.N.
        • Marshall D.T.
        • Stone J.J.
        • et al.
        Does neoadjuvant hormonal therapy improve urinary function when given to men with large prostates undergoing prostate brachytherapy?.
        J Urol. 2010; 183: 634-639
        • Elshaikh M.A.
        • Ulchaker J.C.
        • Reddy C.A.
        Prophylactic tamsulosin (Flomax) in patients undergoing prostate 125I brachytherapy for prostate carcinoma: final report of a double-blind placebo-controlled randomized study.
        Int J Radiat Oncol Biol Phys. 2005; 62: 164-169
        • Sacco D.E.
        • Daller M.
        • Grocela J.A.
        • et al.
        Corticosteroid use after prostate brachytherapy reduces the risk of acute urinary retention.
        BJU Int. 2003; 91: 345-349
        • Carlson T.
        • Ciezki J.
        • Elshaikh M.
        The role of prophylactic Tamsulosin ± dexamethasone in patients undergoing prostate 125I seed implants for prostate carcinoma. A randomized double-blind study.
        Int J Radiat Oncol Biol Phys. 2004; 60 (S269-S270)
        • Carlson T.P.K.M.
        • Ciezki J.P.
        • Elshaikh M.
        • et al.
        The role of prophylactic tamsulosin (Flomax) +/- dexamethasone in patients undergoing prostate i125 seed implants for prostate carcinoma: A randomized double-blidn study.
        Türk Üroloji Dergisi. 2008; 34: 285-290
        • Mierzwa M.L.
        • Barrett W.L.
        • Redmond K.
        Randomized trial to assess the efficacy of intraoperative steroid use in decreasing acute urinary retention after transperineal radioactive iodine-125 implantation for prostate cancer.
        Cancer. 2008; 113: 2605-2609
        • Ling D.C.
        • Chen K.S.
        • Benoit R.M.
        • et al.
        Long-term patient-reported rectal bleeding and bowel-related quality of life after Cs-131 prostate brachytherapy.
        Int J Radiat Oncol Biol Phys. 2019; 104: 622-630
        • Benoit R.M.
        • Smith R.P.
        • Beriwal S.
        Five year prostate-specific antigen outcomes after caesium prostate brachytherapy.
        Clin Oncol (R Coll Radiol). 2014; 26: 776-780
        • Murphy M.K.
        • Piper R.K.
        • Greenwood L.R.
        Evaluation of the new cesium-131 seed for use in low-energy x-ray brachytherapy.
        Med Phys. 2004; 31: 1529-1538
        • Jacobs B.L.
        • Smith R.P.
        • Beriwal S.
        • Benoit R.M.
        Changes in lower urinary tract symptoms after prostate brachytherapy.
        J Contemp Brachyther. 2011; 3: 115-120
        • Smith R.P.
        • Jones H.A.
        • Beriwal S.
        • et al.
        Predictors of urinary morbidity in Cs-131 prostate brachytherapy implants.
        Int J Radiat Oncol Biol Phys. 2011; 81: 745-750
        • Glaser S.M.
        • Chen K.S.
        • Benoit R.M.
        • et al.
        Long-term quality of life in prostate cancer patients treated with cesium-131.
        Int J Radiat Oncol Biol Phys. 2017; 98: 1053-1058
        • Kehwar T.S.
        • Jones H.A.
        • Huq M.S.
        • et al.
        Effect of edema associated with 131Cs prostate permanent seed implants on dosimetric quality indices.
        Med Phys. 2009; 36: 3536-3542
        • Tsumura H.
        • Satoh T.
        • Ishiyama H.
        Comparison of prophylactic naftopidil, tamsulosin, and silodosin for 125I brachytherapy-induced lower urinary tract symptoms in patients with prostate cancer: randomized controlled trial.
        Int J Radiat Oncol Biol Phys. 2011; 81: e385-e392
        • Yan M.
        • Xue P.
        • Wang K.
        • et al.
        Does combination therapy with tamsulosin and trospium chloride improve lower urinary tract symptoms after SEEDS brachytherapy for prostate cancer compared with tamsulosin alone?: A prospective, randomized, controlled trial.
        Strahlenther Onkol. 2017; 193: 714-721
        • Katzung B.
        Basic and clinical pharmacology.
        Mcgraw-Hill, New York2015 (13th ed)
        • Lee T.K.
        • Breau R.H.
        • Mallick R.
        • Eapen L.
        A systematic review of expanded prostate cancer index composite (EPIC) quality of life after surgery or radiation treatment.
        Can J Urol. 2015; 22: 7599-7606
        • Bucci J.
        • Morris W.J.
        • Keyes M.
        • et al.
        Predictive factors of urinary retention following prostate brachytherapy.
        Int J Radiat Oncol Biol Phys. 2002; 53: 91-98
        • Keyes M.
        • Schellenberg D.
        • Moravan V.
        Decline in urinary retention incidence in 805 patients after prostate brachytherapy: The effect of learning curve?.
        Int J Radiat Oncol Biol Phys. 2006; 64: 825-834
        • Terk M.D.
        • Stock R.G.
        • Stone N.N.
        Identification of patients at increased risk for prolonged urinary retention following radioactive seed implantation of the prostate.
        J Urol. 1998; 160: 1379-1382